I am (Bahram Resul, graduated from the college of pharmacy at Baghdad University in 1968. I Attended a PhD program in Medicinal Chemistry at the faculty of Pharmacy, Uppsala University in Sweden. I was working as assistant lecturer in organic chemistry and medicinal chemistry at the faculty of pharmacy, Uppsala university during my Ph.D. program. I Received a Ph.D. in Medicinal Chemistry, in 1982. I was employed at Pharmacia (Now Pfizer) from 1983-1998. I had various positions at Pharmacia during my employment, including head of medicinal chemistry. I am an Associate professor in the department of Neuroscience, Unit of Pharmacology at Uppsala University in Uppsala, Sweden, where I have been employed since leaving Pharmacia. Professor Stjernschantz and I am the inventor of latanoprost (Xalatan) US patent number 5,578, 618. Xalatan is a new drug for the treatment of Glaucoma. Xalatan was approved by the US FDA in 1996. I am also co-authored numerous published papers in the area of medicinal chemistry, pharmacology and ophthalmology (41 papers se attachment 1). I have been the editor of three International Ophthalmology books. I have been an invited speaker at numerous international scientific meetings and presented more than 30 numerous papers related to use of prostaglandins to treat ocular diseases.

I was teaching Organic Chemistry, Stereochemistry and medicinal chemistry at the Faculty of Pharmacy, Uppsala University, Sweden 1977-1982.

I was teaching Pharmacology (peripheral nervous system and Inflammation) at the Faculty of Medicine, Uppsala University, Sweden 1998-2006.

I am also a named inventor on several patents, including multiple patents directed to the use of prostaglandins (se the attachment 2 ). I have received research grants, including grants related to ocular treatments. I have co authored numerous published peer-reviewed papers in the area of prostaglandin research.

I am the founder of the Pharmaceutical manufacturing company Awamedica and was CEO of Awamedica 2006-2018

 

I am currently a dean of the faculty of medicine at the University of Kurdistan Hawler

   
   

1970-1974 Sulaimany University

 

1976-1983 Laboratory assistant, Faculty of Pharmacy, Uppsala, Sweden

 

1983 -1987 Medicinal Chemist, Pharmacia, Uppsala

 

1987-1998 Head of Medicinal Chemistry, prostaglandin Research, Pharmacia, Uppsala, Sweden

 

1998-2006 Associate Professor, Department of Neuroscience,

Unit of Pharmacology. Faculty of Medicine, Uppsala University, Uppsala, Sweden

 

Director of Pharmaceutical and Chemical

Developments at Synphora Ltd (Drug Development Company)

 

2006-2018 CEO

Awamedica Ltd

Drug Manufacturing Company

Kurdistan Region-Iraq

Erbil

 

Current position

Dean

Faculty of Medicine

University of Kurdistan Hawler (UKH)

 

I am the founder of the Pharmaceutical manufacturing company Awamedica and was CEO of Awamedica 2006-2018.

I am the inventor of latanoprost (Xalatan) US patent number 5,578, 618. Xalatan is a new drug for the treatment of Glaucoma. Xalatan was approved by the US FDA in 1996.


     
Title cited by  Year
Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents

B Resul, J Stjernschantz, K No, C Liljebris, G Selen, M Astin, M Karlsson, ...

Journal of medicinal chemistry 36 (2), 243-248

201 1993
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,422,368

166 1995
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,296,504

158 1994
The ocular hypotensive effects and side effects of prostaglandins on the eyes of experimental animals.

LZ Bito, CB Camras, GG Gum, B Resul

Progress in clinical and biological research 312, 349

121 1989
Derivatives of 17-Phenyl-18, 19, 20-trinorprostaglandin F2. alpha. Isopropyl Ester: Potential Antiglaucoma Agents

C Liljebris, G Selen, B Resul, J Stjernschantz, U Hacksell

Journal of medicinal chemistry 38 (2), 289-304

117 1995
Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure: a one-month study

A Alm, J Villumsen, P Törnquist, A Mandahl, J Airaksinen, A Tuulonen, ...

Ophthalmology 100 (9), 1312-1317

106 1993
Prostaglandin-induced iridial pigmentation in primates

G Selén, J Stjernschantz, B Resul

Survey of ophthalmology 41, S125-S128

99 1997
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,321,128

78 1994
Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids

B Resul, J Stjernschantz, G Selén, L Bito

Survey of ophthalmology 41, S47-S52

70 1997
The ocular effects of prostaglandins and the therapeutic potential of a new PGF2 alpha analog, PhXA41 (latanoprost), for glaucoma management.

LZ Bito, J Stjernschantz, B Resul, OC Miranda, S Basu

Journal of lipid mediators 6 (1-3), 535-543

67 1993
Synthesis of a 11C‐labelled prostaglandin F2α analogue using an improved method for stille reactions with [11C]methyl iodide

M Björkman, H Doi, B Resul, M Suzuki, R Noyori, Y Watanabe, ...

Journal of Labelled Compounds and Radiopharmaceuticals: The Official Journal …

63 2000
Facile preparation of the enantiomers of 3-acetoxyquinuclidine and 3-quinuclidinol.

B Ringdahl, B Resul, R Dahlbom

Acta Pharmaceutica Suecica 16 (4), 281-283

62 1979
Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment

J Stjernschantz, G Selén, M Astin, B Resul

Progress in retinal and eye research 19 (4), 459-496

61 2000
Method and means for prevention of cataract

J Stjernschantz, B Resul

US Patent 5,773,472

58 1998
Prostaglanddin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,422,369

57 1995
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,578,618

55 1996
N‐Alkyl‐N‐(4‐tert‐amino‐1‐methyl‐2‐butynyl) carboxamides, a new class of potent oxotremorine antagonists

B Resul, R Dahlbom, B Ringdahl, DJ Jenden

Chemischer Informationsdienst 13 (48), no-no

51 1982
Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro

S Basu, B Sjöquist, J Stjernschantz, B Resul

Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) 50 (4), 161-168

47 1994
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 6,030,999

40 2000
Disposition of single oral doses of E‐10‐hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects

L Bertilsson, C Nordin, K Otani, B Resul, M Scheinin, B Siwers, F Sjöqvist

Clinical Pharmacology & Therapeutics 40 (3), 261-267

38 1986
The conversion of 2-chloroalkylamine analogues of oxotremorine to aziridinium ions and their interactions with muscarinic receptors in the guinea pig ileum.

B Ringdahl, B Resul, FJ Ehlert, DJ Jenden, R Dahlbom

Molecular pharmacology 26 (2), 170-179

38 1984
Effect of latanoprost on regional blood flow and capillary permeability in the monkey eye

J Stjernschantz, G Selén, M Astin, M Karlsson, B Resul

Archives of Ophthalmology 117 (10), 1363-1367

37 1999
Stereochemical requirements for central and peripheral muscarinic and antimuscarinic activity of some acetylenic compounds related to oxotremorine

R Dahlbom, DJ Jenden, B Resul, B Ringdahl

British journal of pharmacology 76 (2), 299-304

33 1982
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,627,208

29 1997
Use of prostaglandins

J Stjernschantz, B Resul

US Patent 6,031,001

27 2000
Prostagladin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 7,163,959

24 2007
Overview: Structure-activity relationships of prostaglandin analogues as ocular hypotensive agents

B Resul, J Stjernschantz

Current Opinion on Therapeutic Patents 3 (6), 781-795

24 1993
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,849,791

22 1998
Treatment of depression with E-10-hydroxynortriptyline—a pilot study on biochemical effects and pharmacokinetics

C Nordin, L Bertilsson, ML Dahl, B Resul, G Toresson, F Sjöqvist

Psychopharmacology 103 (3), 287-290

22 1991
Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study

A Aim, J Villumsen, P Tornquist, A Mandahl, J Airaksinen, A Tuulonen, ...

Ophthalmology 100 (9), 1312-7

21 1993
Acetylene compounds of potential pharmacological value. XXVIII. Oxotremorine analogues substituted with a methyl group in the lactam ring.

B Ringdahl, Z Muhi-Eldeen, C Ljunggren, B Karlen, B Resul, R Dahlbom

Acta Pharmaceutica Suecica 16 (2), 89-94

21 1979
Presence of a 15-ketoprostaglandin delta 13-reductase in porcine cornea.

S Basu, B Sjöquist, B Resul, J Stjernschantz

Acta chemica Scandinavica (Copenhagen, Denmark: 1989) 46 (1), 108

17 1992
Eicosanoids as a new class of ocular hypotensive agents. 3. Prostaglandin A2-1-isopropyl ester is the most potent reported hypotensive agent on feline eyes

LZ Bito, OC Miranda, MR Tendler, B Resul

Experimental eye research 50 (4), 419-428

16 1990
EFFECTS OF PHXA34 AND PHDH100A, 2 PHENYL SUBSTITUTED PROSTAGLANDIN ESTERS, ON AQUEOUS-HUMOR DYNAMICS AND MICROCIRCULATION IN THE MONKEY EYE

G Selen, M Karlsson, M Astin, J Stjernschantz, B Resul

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 32 (4), 869-869

14 1991
Method for treatment of female sexual dysfunction

J Stjernschantz, B Resul

US Patent 6,562,868

13 2003
Muscarinic activity of some secondary and tertiary amines and quaternary ammonium salts structurally related to oxotremorine

B Resul, B Ringdahl, R Dahlbom, DJ Jenden

European journal of pharmacology 87 (4), 387-396

13 1983
Acetylene compounds of potential pharmacological value. XXX. Synthesis and pharmacological properties of N-(4-pyrrolidino-2-pentynyl)-substituted 2-pyrrolidone and succinimide.

B Resul, B Ringdahl, R Dahlbom

Acta pharmaceutica Suecica 16 (3), 161-165

13 1979
Synthesis and pharmacological properties of N‐[4‐(1‐azetidinyl)‐2‐ butynyl]‐2‐pyrrolidone, a highly potent oxotremorine‐like agent

B Resul, T Lewander, T Zetterström, B Ringdahl, Z MUHI‐ELDEEN, ...

Journal of Pharmacy and Pharmacology 32 (1), 439-440

12 1980
Stereoselectivity of some oxotremorine antagonists containing two chiral centres

B RINGDAHL, B RESUL, R DAHLBOM

Journal of Pharmacy and Pharmacology 31 (1), 837-839

12 1979
The pharmacological assessment of a new, potent oxotremorine analogue in mice and rats

B Resul, T Lewander, B Ringdahl, T Zetterström, R Dahlbom

European journal of pharmacology 80 (2-3), 209-215

11 1982
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 6,429,226

10 2002
Method for synthesis of prostaglandin derivatives

B Resul

US Patent 5,359,095

10 1994
Acetylene compounds of potential pharmacological value. XXXI. Studies on N-(4-tert-amino-2-butynyl) carboxamides as muscarinic agonists.

B Resul, B Ringdahl, U Hacksell, U Svensson, R Dahlbom

Acta pharmaceutica Suecica 16 (4), 225

10 1979
Regio- and Stereoselective Reactions of 17-Phenyl-18,19,20-trinorprostaglandin F2αIsopropyl Ester

C Liljebris, BM Nilsson, B Resul, U Hacksell

The Journal of organic chemistry 61 (12), 4028-4034

9 1996
Method and composition for treatment of gastric and duodenal disorders

J Stjernschantz, B Resul

US Patent 5,223,537

9 1993
Muscarinic activity in the isolated guinea pig ileum of some carboxamides related to oxotremorine

B Ringdahl, B Resul, DJ Jenden, R Dahlbom

European journal of pharmacology 85 (1), 79-83

9 1982
Method and composition for treatment of erectile dysfunction

J Stjernschantz, B Resul

US Patent 6,476,074

7 2002
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 6,417,230

7 2002
Method and means for prevention and treatment of secondary cataract

J Stjernschantz, B Resul

US Patent 5,760,075

7 1998
Process for the preparation of 13, 14-dihydro-15 (R)-17-phenyl-18, 19, 20-trinor-PGF2α isopropyl ester

J Ivanics, T Szabo, I Hermecz, G Dalmadi, J Ivanics, G Kovacs, R Bahram

US Patent 5,466,833

7 1995
The systemic pharmacokinetics of latanoprost in man after intravenous and topical administration

B Sjoquist, P Byding, B Resul, J Stjernschantz

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 35 (4), 2220-2220

7 1994
Palladium catalyzed syntheses of phenyl-substittuted pgf2α analogues: potential antigluaucoma agents

C Liljebris, B Resul, U Hacksell

Bioorganic & Medicinal Chemistry Letters 3 (2), 241-244

7 1993
Carbon-11-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET)

S Stone-Elander, M Ingvar, P Johnstroem, E Ehrin, B Garmelius, T Greitz, ...

Journal of medicinal chemistry 28 (9), 1325-1328

7 1985
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 6,187,813

6 2001
Phenyl substituted prostaglandin esters-effects in the eye

J Stjernschantz, B Resul, A Marsk, M Astin, C Carrass, M Karlsson, ...

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 32 (4), 1257-1257

6 1991
The pharmacokinetics of latanoprost in the cynomolgus monkey

B Sjoquist, S Basu, B Resul, J Stjernschantz

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 34 (4), 932-932

5 1993
INTRAOCULAR-PRESSURE REDUCING EFFECT OF PHXA41 IN OCULAR HYPERTENSIVE PATIENTS-A PLACEBO CONTROLLED DOUBLE MASKED DOSE FINDING STUDY

A Alm, J Villumsen, P Tornquist, A MANDAHL, J AIRAKSINEN, ...

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 33 (4), 1247-1247

5 1992
Fluorescein angiographic study of the fundus in phakic and aphakic monkey eyes treated with PhXA41

M Astin, M Gjotterberg, A Holst, G Selen, B Resul, J Stjernschantz

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 33 (4), 1078-1078

5 1992
ACETYLENE COMPOUNDS OF POTENTIAL PHARMACOLOGICAL VALUE. XXXV. THE β‐LACTAM ANALOG OF OXOTREMORINE

B Resul, B Ringdahl, R Dahlbom

Chemischer Informationsdienst 12 (47), no-no

5 1981
CIRCULAR-DICHROISM AND CONFORMATION OF TERTIARY AMIDES-N-ACYLPYRROLIDINES

B Ringdahl, B Resul, JC Craig

CHEMICA SCRIPTA 16 (5), 169-172

5 1980
Antibiogram of Escherichia coli isolated from different hospitals wastewater in Erbil City, Iraq

RJ Aziz, FS Al-Zubaidy, HJ Al-Mathkhury, B Resul, J Musenga

Iraqi Journal of Science 55 (2), 341-351

4 2014
Thioprostaglandins and-prostaglandin-like compounds and therapeutic uses thereof

JW Stjernschantz, B Resul, LZ Bito

US Patent 5,516,796

4 1996
Receptor profile of PhXA41, a new phenyl substituted prostaglandin ester

M Karlason, G Selén, J Stiernschantz, B Resul

Experimental Eye Research 55, 50

4 1992
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,114,971

3 1992
Method for composition for treatment of gastric and duodenal disorders

J Stjernschantz, B Resul

US Patent 5,510,382

2 1996
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

J Stjernschantz, B Resul

US Patent App. 10/330,846

1 2003
Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula

J Stjernschantz, B Resul

US Patent 6,495,563

1 2002
Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents.[Erratum to document cited in CA118 (11): 101683k]

B Resul, J Stjernschantz, K No, C Liljebris, G Selen, M Astin, M Karlsson, ...

Journal of Medicinal Chemistry 36 (15), 2242-2242

1 1993
Stereoselectivity of Some Muscarinic and Antimuscarinic Agents Related to Oxotremorine

R Dahlbom, B Ringdahl, B Resul, DJ Jenden

Dynamics of cholinergic function, 385-393

1 1986
ACETYLENE-COMPOUNDS OF POTENTIAL PHARMACOLOGICAL VALUE. 36. N-ALKYL-N-(4-TERT-AMINO-1-METHYL-2-BUTYNYL) CARBOXAMIDES, A NEW CLASS OF POTENT OXOTREMORINE ANTAGONISTS

B Resul, R DAHLBOM, B RINGDAHL, DJ JENDEN

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 17 (4), 317-322

1 1982
Los Angeles, California 90024, US A.

R Dahlbom, B Ringdahl, B Resul, DJ Jenden

Dynamics of Cholinergic Function 30, 385

  2013
Composition and method for the treatment of psoriasis

J Stjernschantz, B Resul

US Patent App. 11/204,491

  2006
TWICE MONTHLY BIBUOGRAPHY ON PROSTAGLANDINS BIOLOGY-EARLY NOVEMBER PREPARED BY SUBIS, MANSION HOUSE, 19 KINGFIELD ROAD, SHEFFIELD Sll 9AS

MH Gelb, MK Jain, OG Berg, Z Diamant, L JWJ, JD Pickard, V Walker, ...

FASEB JOURNAL 8 (12), 916

  1994
Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects

L Bertilsson, C Nordin, K Otani, B Resul, M Scheinin, B Siwers, F Sjoqvist

Journal of Clinical Psychopharmacology 7 (1), 47

  1987
FATE OF A SINGLE DOSE OF E-10-HYDROXYNORTRIPTYLINE IN MAN AND ITS EFFECTS ON PLASMA-LEVELS OF NORADRENALINE

M SCHEININ, L BERTILSSON, C NORDIN, K OTANI, B RESUL, ...

ACTA PHYSIOLOGICA SCANDINAVICA 124, 259-259

  1985
11C-4-isopropylantipyrine as a possible blood flow tracer in PET studies - synthesis and evaluation

S Stone-Elander, P Johnstroem, E Ehrin, JLG Nilsson, B Resul, ...

Nuclear medicine in research and practice

  1984
ACETYLENE-COMPOUNDS OF POTENTIAL PHARMACOLOGICAL VALUE. 38. MUSCARINIC ACTIVITY OF SOME SECONDARY AND TERTIARY-AMINES AND QUATERNARY AMMONIUM-SALTS STRUCTURALLY RELATED TO …

B RESUL, B RINGDAHL, R DAHLBOM, DJ JENDEN

EUROPEAN JOURNAL OF PHARMACOLOGY 87 (4), 387-396

  1983
Structural and steric aspects of acetylenic compounds related to oxotremorine

B Resul

Acta Universitatis Upsaliensis

  1982
STEREOCHEMICAL REQUIREMENTS FOR MUSCARINIC AND ANTIMUSCARINIC ACTIVITY IN SOME TERTIARY ACETYLENIC AMINES RELATED TO OXOTREMORINE

B RINGDAHL, B RESUL, R DAHLBOM, D JENDEN

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 182 (AUG), 23-MEDI

  1981

Buy a Rubik's Cube puzzle, the best Christmas present for anyone in the family.

1968 BSc. Pharmacy

College of Pharmacy, Baghdad,  Iraq

 

1982 PhD Medicinal Chemistry, Faculty of Pharmacy, Uppsala, Sweden

 

1995 Associate Professor, Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Sweden

 

I am co-authored numerous published papers in the area of medicinal chemistry, pharmacology and ophthalmology. I have been the editor of three International Ophthalmology books. I have been an invited speaker at numerous international scientific meetings and presented more than 30 numerous papers related to use of prostaglandins to treat ocular diseases.

1. 1997 Williame-Upjohn prize In Recognition of Special Accomplishment

2. 1998 Hungarian Academy of Science for outstanding contribution in Medicinal Chemistry

3. 2004 Swedish Academy of Pharmaceutical Sciences for outstanding contribution in Medicinal Chemistry

     
Title cited by  Year
Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents

B Resul, J Stjernschantz, K No, C Liljebris, G Selen, M Astin, M Karlsson, ...

Journal of medicinal chemistry 36 (2), 243-248

201 1993
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,422,368

166 1995
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,296,504

158 1994
The ocular hypotensive effects and side effects of prostaglandins on the eyes of experimental animals.

LZ Bito, CB Camras, GG Gum, B Resul

Progress in clinical and biological research 312, 349

121 1989
Derivatives of 17-Phenyl-18, 19, 20-trinorprostaglandin F2. alpha. Isopropyl Ester: Potential Antiglaucoma Agents

C Liljebris, G Selen, B Resul, J Stjernschantz, U Hacksell

Journal of medicinal chemistry 38 (2), 289-304

117 1995
Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure: a one-month study

A Alm, J Villumsen, P Törnquist, A Mandahl, J Airaksinen, A Tuulonen, ...

Ophthalmology 100 (9), 1312-1317

106 1993
Prostaglandin-induced iridial pigmentation in primates

G Selén, J Stjernschantz, B Resul

Survey of ophthalmology 41, S125-S128

99 1997
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,321,128

78 1994
Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids

B Resul, J Stjernschantz, G Selén, L Bito

Survey of ophthalmology 41, S47-S52

70 1997
The ocular effects of prostaglandins and the therapeutic potential of a new PGF2 alpha analog, PhXA41 (latanoprost), for glaucoma management.

LZ Bito, J Stjernschantz, B Resul, OC Miranda, S Basu

Journal of lipid mediators 6 (1-3), 535-543

67 1993
Synthesis of a 11C‐labelled prostaglandin F2α analogue using an improved method for stille reactions with [11C]methyl iodide

M Björkman, H Doi, B Resul, M Suzuki, R Noyori, Y Watanabe, ...

Journal of Labelled Compounds and Radiopharmaceuticals: The Official Journal …

63 2000
Facile preparation of the enantiomers of 3-acetoxyquinuclidine and 3-quinuclidinol.

B Ringdahl, B Resul, R Dahlbom

Acta Pharmaceutica Suecica 16 (4), 281-283

62 1979
Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment

J Stjernschantz, G Selén, M Astin, B Resul

Progress in retinal and eye research 19 (4), 459-496

61 2000
Method and means for prevention of cataract

J Stjernschantz, B Resul

US Patent 5,773,472

58 1998
Prostaglanddin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,422,369

57 1995
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,578,618

55 1996
N‐Alkyl‐N‐(4‐tert‐amino‐1‐methyl‐2‐butynyl) carboxamides, a new class of potent oxotremorine antagonists

B Resul, R Dahlbom, B Ringdahl, DJ Jenden

Chemischer Informationsdienst 13 (48), no-no

51 1982
Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro

S Basu, B Sjöquist, J Stjernschantz, B Resul

Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) 50 (4), 161-168

47 1994
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 6,030,999

40 2000
Disposition of single oral doses of E‐10‐hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects

L Bertilsson, C Nordin, K Otani, B Resul, M Scheinin, B Siwers, F Sjöqvist

Clinical Pharmacology & Therapeutics 40 (3), 261-267

38 1986
The conversion of 2-chloroalkylamine analogues of oxotremorine to aziridinium ions and their interactions with muscarinic receptors in the guinea pig ileum.

B Ringdahl, B Resul, FJ Ehlert, DJ Jenden, R Dahlbom

Molecular pharmacology 26 (2), 170-179

38 1984
Effect of latanoprost on regional blood flow and capillary permeability in the monkey eye

J Stjernschantz, G Selén, M Astin, M Karlsson, B Resul

Archives of Ophthalmology 117 (10), 1363-1367

37 1999
Stereochemical requirements for central and peripheral muscarinic and antimuscarinic activity of some acetylenic compounds related to oxotremorine

R Dahlbom, DJ Jenden, B Resul, B Ringdahl

British journal of pharmacology 76 (2), 299-304

33 1982
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,627,208

29 1997
Use of prostaglandins

J Stjernschantz, B Resul

US Patent 6,031,001

27 2000
Prostagladin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 7,163,959

24 2007
Overview: Structure-activity relationships of prostaglandin analogues as ocular hypotensive agents

B Resul, J Stjernschantz

Current Opinion on Therapeutic Patents 3 (6), 781-795

24 1993
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,849,791

22 1998
Treatment of depression with E-10-hydroxynortriptyline—a pilot study on biochemical effects and pharmacokinetics

C Nordin, L Bertilsson, ML Dahl, B Resul, G Toresson, F Sjöqvist

Psychopharmacology 103 (3), 287-290

22 1991
Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study

A Aim, J Villumsen, P Tornquist, A Mandahl, J Airaksinen, A Tuulonen, ...

Ophthalmology 100 (9), 1312-7

21 1993
Acetylene compounds of potential pharmacological value. XXVIII. Oxotremorine analogues substituted with a methyl group in the lactam ring.

B Ringdahl, Z Muhi-Eldeen, C Ljunggren, B Karlen, B Resul, R Dahlbom

Acta Pharmaceutica Suecica 16 (2), 89-94

21 1979
Presence of a 15-ketoprostaglandin delta 13-reductase in porcine cornea.

S Basu, B Sjöquist, B Resul, J Stjernschantz

Acta chemica Scandinavica (Copenhagen, Denmark: 1989) 46 (1), 108

17 1992
Eicosanoids as a new class of ocular hypotensive agents. 3. Prostaglandin A2-1-isopropyl ester is the most potent reported hypotensive agent on feline eyes

LZ Bito, OC Miranda, MR Tendler, B Resul

Experimental eye research 50 (4), 419-428

16 1990
EFFECTS OF PHXA34 AND PHDH100A, 2 PHENYL SUBSTITUTED PROSTAGLANDIN ESTERS, ON AQUEOUS-HUMOR DYNAMICS AND MICROCIRCULATION IN THE MONKEY EYE

G Selen, M Karlsson, M Astin, J Stjernschantz, B Resul

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 32 (4), 869-869

14 1991
Method for treatment of female sexual dysfunction

J Stjernschantz, B Resul

US Patent 6,562,868

13 2003
Muscarinic activity of some secondary and tertiary amines and quaternary ammonium salts structurally related to oxotremorine

B Resul, B Ringdahl, R Dahlbom, DJ Jenden

European journal of pharmacology 87 (4), 387-396

13 1983
Acetylene compounds of potential pharmacological value. XXX. Synthesis and pharmacological properties of N-(4-pyrrolidino-2-pentynyl)-substituted 2-pyrrolidone and succinimide.

B Resul, B Ringdahl, R Dahlbom

Acta pharmaceutica Suecica 16 (3), 161-165

13 1979
Synthesis and pharmacological properties of N‐[4‐(1‐azetidinyl)‐2‐ butynyl]‐2‐pyrrolidone, a highly potent oxotremorine‐like agent

B Resul, T Lewander, T Zetterström, B Ringdahl, Z MUHI‐ELDEEN, ...

Journal of Pharmacy and Pharmacology 32 (1), 439-440

12 1980
Stereoselectivity of some oxotremorine antagonists containing two chiral centres

B RINGDAHL, B RESUL, R DAHLBOM

Journal of Pharmacy and Pharmacology 31 (1), 837-839

12 1979
The pharmacological assessment of a new, potent oxotremorine analogue in mice and rats

B Resul, T Lewander, B Ringdahl, T Zetterström, R Dahlbom

European journal of pharmacology 80 (2-3), 209-215

11 1982
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 6,429,226

10 2002
Method for synthesis of prostaglandin derivatives

B Resul

US Patent 5,359,095

10 1994
Acetylene compounds of potential pharmacological value. XXXI. Studies on N-(4-tert-amino-2-butynyl) carboxamides as muscarinic agonists.

B Resul, B Ringdahl, U Hacksell, U Svensson, R Dahlbom

Acta pharmaceutica Suecica 16 (4), 225

10 1979
Regio- and Stereoselective Reactions of 17-Phenyl-18,19,20-trinorprostaglandin F2αIsopropyl Ester

C Liljebris, BM Nilsson, B Resul, U Hacksell

The Journal of organic chemistry 61 (12), 4028-4034

9 1996
Method and composition for treatment of gastric and duodenal disorders

J Stjernschantz, B Resul

US Patent 5,223,537

9 1993
Muscarinic activity in the isolated guinea pig ileum of some carboxamides related to oxotremorine

B Ringdahl, B Resul, DJ Jenden, R Dahlbom

European journal of pharmacology 85 (1), 79-83

9 1982
Method and composition for treatment of erectile dysfunction

J Stjernschantz, B Resul

US Patent 6,476,074

7 2002
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 6,417,230

7 2002
Method and means for prevention and treatment of secondary cataract

J Stjernschantz, B Resul

US Patent 5,760,075

7 1998
Process for the preparation of 13, 14-dihydro-15 (R)-17-phenyl-18, 19, 20-trinor-PGF2α isopropyl ester

J Ivanics, T Szabo, I Hermecz, G Dalmadi, J Ivanics, G Kovacs, R Bahram

US Patent 5,466,833

7 1995
The systemic pharmacokinetics of latanoprost in man after intravenous and topical administration

B Sjoquist, P Byding, B Resul, J Stjernschantz

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 35 (4), 2220-2220

7 1994
Palladium catalyzed syntheses of phenyl-substittuted pgf2α analogues: potential antigluaucoma agents

C Liljebris, B Resul, U Hacksell

Bioorganic & Medicinal Chemistry Letters 3 (2), 241-244

7 1993
Carbon-11-labeled 4-isopropylantipyrine: preparation and biological evaluation as a blood flow tracer in positron emission tomography (PET)

S Stone-Elander, M Ingvar, P Johnstroem, E Ehrin, B Garmelius, T Greitz, ...

Journal of medicinal chemistry 28 (9), 1325-1328

7 1985
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 6,187,813

6 2001
Phenyl substituted prostaglandin esters-effects in the eye

J Stjernschantz, B Resul, A Marsk, M Astin, C Carrass, M Karlsson, ...

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 32 (4), 1257-1257

6 1991
The pharmacokinetics of latanoprost in the cynomolgus monkey

B Sjoquist, S Basu, B Resul, J Stjernschantz

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 34 (4), 932-932

5 1993
INTRAOCULAR-PRESSURE REDUCING EFFECT OF PHXA41 IN OCULAR HYPERTENSIVE PATIENTS-A PLACEBO CONTROLLED DOUBLE MASKED DOSE FINDING STUDY

A Alm, J Villumsen, P Tornquist, A MANDAHL, J AIRAKSINEN, ...

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 33 (4), 1247-1247

5 1992
Fluorescein angiographic study of the fundus in phakic and aphakic monkey eyes treated with PhXA41

M Astin, M Gjotterberg, A Holst, G Selen, B Resul, J Stjernschantz

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 33 (4), 1078-1078

5 1992
ACETYLENE COMPOUNDS OF POTENTIAL PHARMACOLOGICAL VALUE. XXXV. THE β‐LACTAM ANALOG OF OXOTREMORINE

B Resul, B Ringdahl, R Dahlbom

Chemischer Informationsdienst 12 (47), no-no

5 1981
CIRCULAR-DICHROISM AND CONFORMATION OF TERTIARY AMIDES-N-ACYLPYRROLIDINES

B Ringdahl, B Resul, JC Craig

CHEMICA SCRIPTA 16 (5), 169-172

5 1980
Antibiogram of Escherichia coli isolated from different hospitals wastewater in Erbil City, Iraq

RJ Aziz, FS Al-Zubaidy, HJ Al-Mathkhury, B Resul, J Musenga

Iraqi Journal of Science 55 (2), 341-351

4 2014
Thioprostaglandins and-prostaglandin-like compounds and therapeutic uses thereof

JW Stjernschantz, B Resul, LZ Bito

US Patent 5,516,796

4 1996
Receptor profile of PhXA41, a new phenyl substituted prostaglandin ester

M Karlason, G Selén, J Stiernschantz, B Resul

Experimental Eye Research 55, 50

4 1992
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

JW Stjernschantz, B Resul

US Patent 5,114,971

3 1992
Method for composition for treatment of gastric and duodenal disorders

J Stjernschantz, B Resul

US Patent 5,510,382

2 1996
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

J Stjernschantz, B Resul

US Patent App. 10/330,846

1 2003
Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula

J Stjernschantz, B Resul

US Patent 6,495,563

1 2002
Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents.[Erratum to document cited in CA118 (11): 101683k]

B Resul, J Stjernschantz, K No, C Liljebris, G Selen, M Astin, M Karlsson, ...

Journal of Medicinal Chemistry 36 (15), 2242-2242

1 1993
Stereoselectivity of Some Muscarinic and Antimuscarinic Agents Related to Oxotremorine

R Dahlbom, B Ringdahl, B Resul, DJ Jenden

Dynamics of cholinergic function, 385-393

1 1986
ACETYLENE-COMPOUNDS OF POTENTIAL PHARMACOLOGICAL VALUE. 36. N-ALKYL-N-(4-TERT-AMINO-1-METHYL-2-BUTYNYL) CARBOXAMIDES, A NEW CLASS OF POTENT OXOTREMORINE ANTAGONISTS

B Resul, R DAHLBOM, B RINGDAHL, DJ JENDEN

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 17 (4), 317-322

1 1982
Los Angeles, California 90024, US A.

R Dahlbom, B Ringdahl, B Resul, DJ Jenden

Dynamics of Cholinergic Function 30, 385

  2013
Composition and method for the treatment of psoriasis

J Stjernschantz, B Resul

US Patent App. 11/204,491

  2006
TWICE MONTHLY BIBUOGRAPHY ON PROSTAGLANDINS BIOLOGY-EARLY NOVEMBER PREPARED BY SUBIS, MANSION HOUSE, 19 KINGFIELD ROAD, SHEFFIELD Sll 9AS

MH Gelb, MK Jain, OG Berg, Z Diamant, L JWJ, JD Pickard, V Walker, ...

FASEB JOURNAL 8 (12), 916

  1994
Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects

L Bertilsson, C Nordin, K Otani, B Resul, M Scheinin, B Siwers, F Sjoqvist

Journal of Clinical Psychopharmacology 7 (1), 47

  1987
FATE OF A SINGLE DOSE OF E-10-HYDROXYNORTRIPTYLINE IN MAN AND ITS EFFECTS ON PLASMA-LEVELS OF NORADRENALINE

M SCHEININ, L BERTILSSON, C NORDIN, K OTANI, B RESUL, ...

ACTA PHYSIOLOGICA SCANDINAVICA 124, 259-259

  1985
11C-4-isopropylantipyrine as a possible blood flow tracer in PET studies - synthesis and evaluation

S Stone-Elander, P Johnstroem, E Ehrin, JLG Nilsson, B Resul, ...

Nuclear medicine in research and practice

  1984
ACETYLENE-COMPOUNDS OF POTENTIAL PHARMACOLOGICAL VALUE. 38. MUSCARINIC ACTIVITY OF SOME SECONDARY AND TERTIARY-AMINES AND QUATERNARY AMMONIUM-SALTS STRUCTURALLY RELATED TO …

B RESUL, B RINGDAHL, R DAHLBOM, DJ JENDEN

EUROPEAN JOURNAL OF PHARMACOLOGY 87 (4), 387-396

  1983
Structural and steric aspects of acetylenic compounds related to oxotremorine

B Resul

Acta Universitatis Upsaliensis

  1982
STEREOCHEMICAL REQUIREMENTS FOR MUSCARINIC AND ANTIMUSCARINIC ACTIVITY IN SOME TERTIARY ACETYLENIC AMINES RELATED TO OXOTREMORINE

B RINGDAHL, B RESUL, R DAHLBOM, D JENDEN

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 182 (AUG), 23-MEDI

  1981

Buy a Rubik's Cube puzzle, the best Christmas present for anyone in the family.

I have received research grants, including grants related to ocular treatments. I have co authored numerous published peer-reviewed papers in the area of prostaglandin research. 

This information is private
        Share by: